Terminal2 — Card #00: [Diagnosis Name]

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of severe aortic stenosis at end of life. What the hospice team needs to understand on day one.

US Severe AS Prevalence

~1.5 M

Approximately 1.5 million Americans live with severe aortic stenosis — the most common valvular heart disease requiring intervention in developed countries.^[1]

Age-Related Prevalence

8–10%

2–5% of adults over 65 have significant AS; 8–10% of adults over 80. This is a disease of aging and progressive calcification of a valve that has opened and closed 3 billion times.^[2]

Symptom Onset Mortality

1–5 yr

Median survival without intervention after symptom onset: angina 3–5 years, syncope 2–3 years, dyspnea/HF 1–2 years. The classic Selzer triad defines urgency and prognosis.^[3]

TAVR Ineligibility Rate

~20–30%

Approximately 20–30% of patients evaluated for TAVR are declined due to frailty, prohibitive comorbidity burden, or hostile anatomy. These patients define the hospice population for this card.^[4]

Aortic stenosis is the progressive calcification and narrowing of the aortic valve — the gatekeeping valve between the left ventricle and the aorta that controls all blood flow leaving the heart's main pumping chamber. In a healthy valve, the orifice area is 3–4 cm², allowing blood to flow with minimal resistance. Over decades of mechanical stress, the valve leaflets accumulate calcium, stiffen, and narrow. When the valve area falls below 1.0 cm², the stenosis is classified as severe. The left ventricle responds to this increasing obstruction by hypertrophying — the muscle wall thickens to generate the enormous pressures required to push blood through the narrowed opening. For years, this compensation maintains near-normal cardiac output. The patient walks, works, and lives without symptoms while the ventricle silently remodels itself around an obstruction that is growing worse with every heartbeat.^[1]

Then the compensation fails. The hypertrophied ventricle reaches its physiological limit, and symptoms begin — the classic triad described by Ross and Braunwald in 1968: angina (myocardial oxygen demand exceeds supply through the narrowed coronary orifices), syncope (cardiac output cannot increase with exertion, and the brain is transiently underperfused), and dyspnea (left ventricular filling pressures rise, causing pulmonary congestion and heart failure). Once symptoms appear, the natural history is one of the most sharply defined in all of cardiology: median survival with angina is 3–5 years, with syncope 2–3 years, and with heart failure 1–2 years without intervention. The patient who presents with all three symptoms has a median survival of less than one year.^[3]

What makes aortic stenosis unique in hospice is the mechanical nature of the obstruction. There is no medication that opens a calcified valve. No drug dissolves the calcium, restores leaflet mobility, or widens the orifice. Medical therapy manages the consequences of obstruction — the fluid overload, the angina, the arrhythmias — but it cannot address the cause. The patient who is not a TAVR candidate, or who has chosen not to proceed with intervention, is living with an irreversible mechanical problem for which medicine is a palliative tool, not a solution. Understanding this distinction is the foundation of every clinical and conversational decision in AS hospice care.^[5]

🧭 Clinical framing

The aortic valve sits between the left ventricle and the aorta — the single exit point for all blood leaving the heart. In severe AS, this valve has calcified from a normal area of 3–4 cm² to less than 1.0 cm². The left ventricle has hypertrophied massively to compensate, generating systolic pressures of 200+ mmHg to force blood through the narrowed opening. This compensation maintained normal output for years — but it has now failed. The symptoms the patient experiences — dyspnea, syncope, angina — are the signs that the ventricle can no longer keep up with the obstruction. Every medication decision in AS hospice revolves around two principles: maintain adequate preload for the stiff, hypertrophied ventricle, and avoid vasodilation that drops blood pressure without increasing output through the fixed obstruction. This is the narrowest therapeutic window in all of cardiac hospice.^[6]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Every other cardiac patient I see, I'm managing a failing muscle. With AS, I'm managing a stuck door. The muscle behind it might still be strong — but it doesn't matter because the door won't open. No pill opens that door. Once you understand that, every conversation with the family gets clearer: we are managing what happens behind a door that cannot be fixed."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read the echo report and understand what it means.

Echocardiogram — Gold Standard

Guideline

The foundational diagnostic tool for aortic stenosis. Defines severity by three key parameters — know these numbers from the most recent echo report:^[7]

Aortic valve area (AVA): Calculated by continuity equation and planimetry. AVA <1.0 cm² = severe AS. AVA <0.6 cm² = critical AS.^[7]
Mean pressure gradient: >40 mmHg = severe AS. Represents the average pressure difference across the stenotic valve during systole.^[7]
Peak aortic jet velocity: >4.0 m/s = severe AS. Measured by continuous-wave Doppler. The velocity increases as the stenosis worsens and the ventricle pushes harder.^[7]
Low-flow low-gradient AS: A specific challenging subtype — AVA <1.0 cm² but mean gradient <40 mmHg. Occurs with reduced EF (classic low-flow) or preserved EF (paradoxical low-flow). Requires dobutamine stress echo or CT calcium scoring for confirmation. Prognostically worse.^[8]
Ejection fraction (EF): May be preserved (≥50%) early; reduced EF (<50%) indicates LV decompensation and worse prognosis.

Cardiac Catheterization

Invasive

Invasive hemodynamic assessment: Confirmatory when echocardiographic data is discordant or technically inadequate. Direct measurement of transvalvular pressure gradient via catheter across the aortic valve.^[7]
Coronary angiography: Performed simultaneously — coronary artery disease co-exists in 50–75% of surgical AS candidates and must be assessed for TAVR/SAVR planning. The AS patient with concurrent CAD has a compounded ischemia burden.^[9]
Left ventriculography: Assesses LV function and mitral regurgitation severity when echo is inconclusive.

CT Aortic Angiography — TAVR Planning

Guideline

Aortic root anatomy: Annular size and shape (elliptical, not circular), leaflet morphology (bicuspid vs. tricuspid), coronary ostial heights, and sinus of Valsalva dimensions — all critical for TAVR valve sizing.^[10]
Access vessel anatomy: Femoral, subclavian, and alternative access route assessment — iliofemoral calcification or tortuosity may preclude transfemoral TAVR.^[10]
Aortic valve calcium scoring: Used to confirm severity in low-flow low-gradient AS. Calcium score >2,000 AU (men) or >1,200 AU (women) confirms severe AS independent of gradient.^[8]

Dobutamine Stress Echo

Guideline

Low-flow low-gradient AS workup: Distinguishes true severe AS from pseudo-severe AS by assessing contractile reserve under dobutamine infusion.^[8]
True severe AS: Gradient increases (>40 mmHg) with dobutamine while AVA remains <1.0 cm² — the valve is truly stenotic, and the ventricle has reserve to demonstrate it.
Pseudo-severe AS: AVA increases (>1.0 cm²) with dobutamine — the valve opens more when output increases, indicating the low gradient was due to weak flow, not true stenosis.
No contractile reserve: Neither gradient nor AVA changes significantly — poor prognosis regardless of true AS status; indicates severe myocardial disease.^[8]

Physical Examination Findings

Systolic murmur: Harsh crescendo-decrescendo systolic murmur best heard at the right upper sternal border (aortic area), radiating to the carotids. Late-peaking murmur indicates more severe stenosis. In severe calcific AS the murmur may paradoxically diminish as cardiac output falls.^[11]
Pulsus parvus et tardus: Slow-rising and delayed carotid upstroke — a bedside examination finding that correlates with severe AS. Diminished carotid pulse amplitude. Less reliable in elderly patients with stiff arterial walls.^[11]
Diminished or absent A2: The aortic component of S2 becomes soft or absent in calcific severe AS because the stiffened leaflets can no longer close audibly. Paradoxical splitting of S2 may occur.^[11]
S4 gallop: Fourth heart sound from forceful atrial contraction against the stiff, hypertrophied LV — a marker of diastolic dysfunction. Present in most patients with significant LV hypertrophy from AS.^[11]
Sustained apical impulse: Laterally displaced and sustained point of maximal impulse reflecting LV hypertrophy.

ACC/AHA Staging Classification (2020/2021 Guidelines)

Guideline

Stage A — At risk: Bicuspid valve, sclerosis without stenosis. No hemodynamic obstruction. Normal valve hemodynamics.^[7]
Stage B — Progressive AS: Mild-moderate stenosis. AVA >1.5 cm² (mild) or 1.0–1.5 cm² (moderate). Asymptomatic. Peak velocity 2.0–3.9 m/s. Mean gradient <40 mmHg.^[7]
Stage C1 — Asymptomatic severe AS: AVA <1.0 cm², peak velocity ≥4.0 m/s, mean gradient ≥40 mmHg. No symptoms. Normal EF (≥50%). LVEF and exercise testing guide intervention timing.^[7]
Stage C2 — Asymptomatic severe AS with LV dysfunction: Same valve criteria as C1 but LVEF <50%. Intervention indicated even without symptoms.^[7]
Stage D1 — Symptomatic severe high-gradient AS: AVA <1.0 cm², mean gradient ≥40 mmHg, peak velocity ≥4.0 m/s with symptoms (dyspnea, angina, syncope). Definitive intervention indicated if feasible.^[7]
Stage D2 — Symptomatic severe low-flow low-gradient AS with reduced EF: AVA <1.0 cm², mean gradient <40 mmHg, EF <50%. Dobutamine stress echo needed to confirm true severity. Poor prognosis.^[8]
Stage D3 — Symptomatic severe paradoxical low-flow low-gradient AS with normal EF: AVA <1.0 cm², mean gradient <40 mmHg, EF ≥50% but stroke volume index <35 mL/m². Small hypertrophied LV cavity. CT calcium scoring needed for confirmation.^[8]

💡 For families

💡 Para las familias

Your loved one's heart has a valve — like a one-way door — that has become stiff and narrow over many years. The heart muscle behind that valve has been working overtime to push blood through the narrowing. The tests your doctors have done measure how narrow the opening is and how hard the heart is working. At this point, all of the testing is usually complete. The focus now is entirely on keeping your loved one comfortable.

El corazón de su ser querido tiene una válvula — como una puerta de un solo sentido — que se ha vuelto rígida y estrecha con los años. El músculo cardíaco ha trabajado en exceso para empujar la sangre a través de esa apertura. Las pruebas miden cuán estrecha es la apertura y cuánto esfuerzo hace el corazón. En este momento, las pruebas generalmente ya están completas. El enfoque ahora es completamente en la comodidad.

S03Everyone

Causes & Risk Factors

What causes aortic stenosis, who is most at risk, and answering the family's question: "Why did this happen?"

Calcific Degenerative AS (Most Common)

Review

The most common cause of AS in adults over 65 in developed countries. The same risk factors that drive atherosclerosis accelerate leaflet calcification:^[12]

Age: The single strongest risk factor. Valve calcification is a time-dependent process — 3 billion cardiac cycles over a lifetime cause cumulative mechanical stress and calcium deposition.
Hypertension: Increases mechanical stress on valve leaflets and accelerates calcification. Hazard ratio ~1.2–1.5 for AS progression.^[12]
Hyperlipidemia: Lipid infiltration of valve leaflets mirrors atherosclerotic pathophysiology. However, statin therapy does not slow AS progression once calcification is established — this was conclusively shown in the SALTIRE and SEAS trials, despite earlier hope.^[13]
Diabetes mellitus: Insulin resistance and hyperglycemia promote osteogenic differentiation of valve interstitial cells.
Chronic kidney disease: Disordered calcium-phosphate metabolism significantly accelerates valve calcification. CKD patients develop AS earlier and progress faster.^[14]
Smoking: Endothelial damage and oxidative stress contribute to leaflet inflammation and calcification.
Male sex: Men develop AS earlier and with higher calcium burdens at equivalent severity levels.^[12]

CAVD — calcific aortic valve disease — shares pathophysiology with atherosclerosis but is not simply "atherosclerosis of the valve." The calcification is an active, regulated process involving osteoblast-like transformation of valve interstitial cells, not passive calcium deposition.^[12]

Bicuspid Aortic Valve

Review

Most common congenital heart defect: Present in 1–2% of the population. Two leaflets instead of three, creating asymmetric flow dynamics and accelerated mechanical stress.^[15]
Earlier onset of severe AS: Bicuspid valve calcifies decades earlier than a tricuspid valve. Severe AS in bicuspid patients typically presents at ages 50–70 vs. 70–85 in tricuspid valve patients.^[15]
Associated aortopathy: Bicuspid valve is associated with aortic root dilation and ascending aortic aneurysm. Aortic imaging is essential in every bicuspid valve patient — the aorta may be dangerous even when the valve is not yet critical.^[15]
Genetic counseling: First-degree relatives of a bicuspid valve patient have a 9% risk of bicuspid valve — screening echocardiography is recommended for parents, siblings, and children.^[15]

Rheumatic Heart Disease

Review

Mechanism: Post-streptococcal autoimmune valvulitis causing leaflet fusion and commissural fusion rather than pure calcification. Results in combined stenosis and regurgitation.^[16]
Associated mitral valve disease: Rheumatic AS almost always occurs with concurrent mitral valve involvement. Isolated rheumatic AS is rare.
Demographics: Predominantly affects younger patients and those from developing countries with limited access to penicillin prophylaxis for streptococcal pharyngitis. Less common cause in the US but globally the leading cause of AS.^[16]
History: Ask about childhood rheumatic fever, recurrent streptococcal infections, and immigration from regions with high rheumatic heart disease prevalence.

Radiation-Induced AS

Observational

Mechanism: Prior thoracic radiation for breast cancer, Hodgkin lymphoma, esophageal cancer, or other mediastinal malignancies damages valve leaflets and accelerates calcification.^[17]
Latency period: 10–20+ years from radiation exposure to clinically significant AS. May present without traditional AS risk factors in a relatively young patient.
Co-existing radiation damage: Pericardial constriction, coronary ostial stenosis, myocardial fibrosis, and conduction system disease frequently co-exist — the radiation damaged more than just the valve.^[17]
TAVR considerations: Porcelain aorta (heavily calcified ascending aorta) from radiation makes SAVR dangerous; TAVR may be preferred but access vessel radiation damage complicates planning.
Growing population: Increasingly recognized in oncology-cardiology overlap as long-term cancer survivors age.

Natural progression: Regardless of etiology, aortic stenosis progresses at approximately 0.1–0.3 cm²/year reduction in valve area and 3–7 mmHg/year increase in mean gradient. This is the natural history — once the valve area crosses below 1.0 cm² and symptoms begin, the progression to death follows the well-defined Selzer triad timeline. Individual variation exists, but the trajectory is remarkably consistent across populations.^[3]

❤️ For families: "Why did this happen?"

Aortic stenosis in older adults is primarily a disease of time and age. The heart valve has opened and closed more than 3 billion times over a lifetime, and the calcium that has built up on it is a result of decades of normal wear. This is not something your loved one caused. It is not from diet, lifestyle choices, or anything they did wrong. Some people's valves calcify faster — genetics, blood pressure, kidney function, and other medical conditions play a role — but the fundamental cause is the mechanical reality of a valve that has worked for 70, 80, or 90 years. There is no guilt here.^[12]

⚕ Clinician note: Disparities in TAVR access

Black, Hispanic, and Asian Americans are significantly underrepresented in TAVR registries relative to AS prevalence. Studies show that Black patients are 30–40% less likely to be referred for TAVR evaluation compared to white patients with equivalent AS severity and surgical risk profiles. Women are referred later and with more advanced symptoms. Rural patients face geographic barriers to TAVR-capable centers. At hospice enrollment, ask whether TAVR was ever discussed — and if not, whether the patient was simply never offered the conversation. Disparities in referral are documented and real.^[18]

S04ClinicianEveryone

Treatments & Procedures

What interventions this patient may have received, why they were declined, and the critical distinction between treating the valve and treating the consequences of a valve that cannot be treated.

The central clinical fact of this card is that only two interventions treat aortic stenosis itself: surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). Everything else — diuretics, beta-blockers, opioids, rate control agents — manages the downstream consequences of an obstruction that remains fixed. The patient on this card either cannot receive valve replacement or has chosen not to. Understanding what was offered, what was declined, and why is essential context for every care plan decision.^[5]

Surgical Aortic Valve Replacement (SAVR)

RCT

Approach: Median sternotomy, cardiopulmonary bypass, direct excision of calcified native valve and replacement with prosthetic valve.^[5]
Gold standard for: Low and intermediate surgical risk patients (STS-PROM <4%). Proven durable outcomes over 15–20 years with tissue valves.^[19]
Valve types: Tissue (bioprosthetic) valves — standard in patients ≥65; durability 10–20 years; no anticoagulation required. Mechanical valves — lifelong durability; requires lifelong warfarin anticoagulation with INR target 2.5–3.5.^[5]
STS risk scoring: The Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) defines operative risk. STS <4% = low risk; 4–8% = intermediate; >8% = high risk. Know the STS score from the chart.^[19]
Hospice relevance: Know whether prior SAVR was performed and what prosthesis was placed. A bioprosthetic valve may degenerate over 10–15 years, causing recurrent stenosis (valve-in-valve TAVR may be an option). A mechanical valve requires ongoing anticoagulation management.

Transcatheter Aortic Valve Replacement (TAVR)

RCT

Approach: Catheter-based valve implantation without open-heart surgery. Transfemoral access in ~90% of cases; alternative access (subclavian, transaortic, transapical, transcaval) for unfavorable femoral anatomy.^[20]
FDA-approved across all risk categories following PARTNER 1, 2, 3 and Evolut Low Risk trials — from inoperable to low surgical risk.^[20]
Outcomes by risk: 30-day mortality ~2–3% in low-risk patients, ~5–8% in high-risk. 1-year mortality ~10–15% in high-risk, ~24% in inoperable (PARTNER 1B TAVR arm) vs. ~50% with medical management alone.^[21]
Valve types: Balloon-expandable (Edwards SAPIEN 3/Ultra); self-expanding (Medtronic Evolut PRO+/FX). Each has specific anatomic suitability.^[20]
Key complications: Paravalvular leak, conduction disturbance requiring pacemaker (10–20% with self-expanding), stroke (1–3%), vascular access complications, coronary obstruction (rare but fatal).^[20]

Balloon Aortic Valvuloplasty (BAV)

Observational

Mechanism: Percutaneous balloon dilation of the calcified valve. Fractures calcium nodules and temporarily widens the orifice.^[22]
Duration of benefit: 3–6 months of modest gradient reduction before restenosis occurs. Not curative — the calcium reforms and the valve re-narrows.^[22]
Bridge to TAVR: Used when rapid hemodynamic improvement is needed before TAVR in a patient too unstable for immediate valve replacement.^[22]
Palliative use: Appropriate as a standalone palliative procedure when TAVR is not possible and the patient has acute decompensation. Can restore enough function for meaningful quality time. Worth discussing at hospice enrollment before the patient becomes too frail to tolerate even this procedure.^[22]
Risks: Stroke (1–2%), severe aortic regurgitation, vascular complications, 30-day mortality ~5–8%.

TAVR Ineligibility — Why Patients Are Declined

Critical

This is the most clinically important section for this card. Understanding why a patient was declined for TAVR is essential context for the hospice care plan:^[4]

Anatomical ineligibility: Small aortic annulus below TAVR valve sizing range; severe aortic root calcification preventing safe deployment; severe LVOT calcification with annular rupture risk; low coronary ostial heights with coronary obstruction risk; bicuspid valve with complex calcification in select cases.^[10]
Clinical ineligibility — futility: The patient whose STS/frailty assessment indicates that procedural risk exceeds the natural history benefit. The patient who will die in 12 months from untreated AS but also die in 12 months from non-cardiac comorbidity has not been helped by TAVR — the valve is replaced but the survival is unchanged.^[4]
Frailty criteria for TAVR refusal: 5-meter walk time >6 seconds, Katz ADL score <4, severe cognitive impairment, albumin <3.0, BMI extremes, severe sarcopenia. The patient who survives TAVR but cannot rehabilitate, cannot live independently, and cannot benefit from restored valve function has not been helped.^[23]
Patient-directed refusal: The informed patient who understands the natural history and chooses not to proceed with intervention. This is the exercise of patient autonomy — not a failure of medicine. Ensure the refusal was truly informed: did the patient hear the survival numbers?^[5]
Competing mortality: Advanced malignancy, severe COPD with FEV1 <30%, end-stage liver disease, severe pulmonary hypertension — life expectancy <12 months from non-cardiac cause renders TAVR benefit negligible.^[4]

📋 Medical management is not valve management

Once the decision has been made that valve replacement will not occur, every treatment is palliative in nature — managing the consequences of a fixed obstruction. Medical management of severe AS includes careful diuresis, cautious rate control, opioid therapy for angina and dyspnea, and avoidance of vasodilators. These medications improve comfort and may extend life modestly, but they do not change the natural history of the valve disease. Be explicit with the family: the medications we use manage the symptoms the valve causes, but they cannot fix the valve itself.^[6]

S05Clinician

When Therapy Makes Sense

Evidence-based criteria for when intervention or active medical management still offers meaningful benefit. The conversation about TAVR belongs at hospice enrollment if it hasn't happened yet.

TAVR transformed the prognosis of severe symptomatic AS. In the PARTNER 1B trial, 1-year mortality dropped from ~50% with medical management to ~24% with TAVR in patients previously considered inoperable. The most important referral conversation at hospice enrollment is this: has TAVR been evaluated? If a patient has symptomatic severe AS and TAVR has not been formally assessed, the conversation about referral belongs at enrollment — even if the patient is enrolled for frailty and support needs. Some patients enrolled on hospice have TAVR-amenable anatomy that would achieve meaningful functional recovery.^[21]

01
TAVR in technically eligible patients with symptomatic severe AS (Stage D1): Patients with adequate life expectancy from non-cardiac conditions (generally >12 months) and acceptable procedural risk should be evaluated. If evaluation has not occurred and the patient has symptomatic severe AS, initiate the referral conversation even at hospice enrollment. The PARTNER and Evolut trials demonstrated survival benefit across all risk categories.^[20]
02
Balloon aortic valvuloplasty (BAV) as palliative bridge: In patients with acute decompensation who are not immediate TAVR candidates, BAV provides temporary hemodynamic improvement — allows diuresis, stabilization, and reassessment. Can restore enough function for TAVR to be reconsidered. Or provides 3–6 months of improved quality of life in patients who decline TAVR but want symptomatic improvement. Discuss with interventional cardiology at enrollment.^[22]
03
Careful diuresis for pulmonary congestion and CHF component: Furosemide titrated to symptom relief while preserving adequate preload. The AS patient who is volume-overloaded has dyspnea; the AS patient who is over-diuresed has hypotension and worsened cardiac output. Target the wet side of euvolemia — "damp, not dry." Daily weight monitoring with clear parameters for dose adjustment.^[6]
04
Rate control for AF with low-dose beta-blocker: Atrial fibrillation in AS causes acute hemodynamic decompensation because the non-compliant hypertrophied LV depends critically on atrial contraction for filling. Rate control to 60–80 bpm maintains LV filling time and preserves output. Metoprolol succinate 12.5–25 mg daily — start low. Anticoagulation for AF (warfarin or DOAC) — stroke risk from AF is additive to the already elevated embolic risk in calcific AS.^[24]
05
Opioids for dyspnea and angina symptom management: Evidence-based at any stage of severe AS. Morphine 2.5–5 mg SQ q4h reduces dyspnea perception, reduces myocardial oxygen demand by lowering anxiety and work of breathing, and provides angina relief. Appropriate when patient goals explicitly include symptom management with full understanding of natural history. Do not withhold opioids from an AS patient with dyspnea or angina.^[25]
06
Patient goals explicitly include symptom management with disease understanding: A well-informed patient who understands the prognosis — median survival 1–2 years with dyspnea without intervention — and chooses comfort-focused care with medical optimization should receive aggressive symptom management without judgment. This is not "giving up." This is clarity about what medicine can and cannot do for a fixed mechanical obstruction.^[5]

S06Clinician

When It Doesn't

Knowing when intervention stops helping — or was never going to help — is not clinical failure. It is the most important clinical skill in aortic stenosis.

The median time from symptom onset to death in untreated severe AS with heart failure symptoms is 1–2 years. Yet referral to palliative care and hospice in valvular heart disease lags far behind referral in cancer, COPD, and even other cardiac diagnoses. Patients with severe AS are frequently managed with serial "watchful waiting" after TAVR refusal without ever receiving an explicit prognosis discussion or hospice referral. The hospice nurse may be the first person to say the number out loud.^[26]

01
Extreme surgical risk with estimated procedural mortality exceeding natural history mortality: STS-PROM >15–20% with severe frailty. The procedure that is more likely to kill than the untreated disease is not a treatment — it is a burden. When the heart team determines that TAVR risk exceeds benefit, the clinical reality is that the patient's survival depends on medical management alone.^[4]
02
TAVR-ineligible due to hostile anatomy with no alternative access: Severe peripheral vascular disease precluding transfemoral access combined with porcelain aorta, prior chest radiation, or other factors precluding alternative access. When the structural cardiologist says "there is no safe route to the valve," the conversation shifts entirely to comfort-focused care.^[10]
03
Life expectancy <12 months from non-cardiac comorbidity: TAVR benefit requires survival to recovery and beyond — typically 3–6 months to realize functional improvement. The patient with metastatic cancer, end-stage COPD, or advanced dementia with a non-cardiac prognosis of <12 months gains no meaningful survival benefit from valve replacement. The valve may be replaced, but the life is not extended.^[4]
04
Severe dementia or severe frailty rendering meaningful recovery unlikely: 5-meter walk time >6 seconds, Katz ADL score <4, severe cognitive impairment. The patient who survives TAVR but cannot rehabilitate, cannot live independently, cannot participate in their own care, and cannot benefit from restored valve function has undergone a procedure without a meaningful outcome. Frailty is the strongest predictor of poor TAVR outcome.^[23]
05
Estimated survival <6 months with NYHA IV symptoms and low-flow low-gradient AS with reduced EF: The combination of severe AS with severely reduced ejection fraction, low cardiac output, and NYHA class IV symptoms at rest indicates a myocardium that has exhausted all compensatory mechanisms. Even successful valve replacement cannot restore a ventricle that has transitioned to irreversible cardiomyopathy. Hospice enrollment is appropriate.^[8]
06
Patient has made an informed autonomous decision to decline intervention: This is not a failure of medicine. It is the appropriate exercise of patient autonomy. Ensure the decision is truly informed — the patient must have been told: median survival with symptomatic severe AS without intervention is 1–2 years with dyspnea, 2–3 years with syncope, 3–5 years with angina. If they heard these numbers and still choose comfort-focused care, honor that decision completely and build the best comfort care plan possible.^[3]
07
Patient goals shift explicitly to comfort and symptom management at home: When a fully informed patient and family prioritize quality over quantity — time at home, freedom from hospital admissions, symptom control, dignity — that is not giving up. It is a treatment plan. Build it with the same clinical rigor you would bring to pre-procedural TAVR planning.^[26]

📋 The natural history conversation

The most important clinical information in severe symptomatic aortic stenosis is this: median survival after dyspnea onset is 1–2 years without intervention. Most patients have never been told this number. Most cardiologists have not used it in conversation — they say "the valve is getting worse" or "we should keep watching it" without anchoring the family in a specific timeframe. The hospice clinician who asks "Do you know what your prognosis is with the valve the way it is?" will almost always receive an answer that reveals the prognosis was never clearly communicated. Say the number. Say it directly, compassionately, and without hedging. Then build the care plan around it. The family and patient who do not know this number cannot make fully informed decisions about advance care planning, legacy work, family time, or goals.^[3]

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches specific to severe AS without intervention. Grade A = RCT/guideline; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Balloon Aortic Valvuloplasty as Palliative Comfort Procedure

Grade B

Procedure: single session percutaneous balloon dilation; repeat at 3–6 month intervals if clinically indicated

BAV achieves temporary gradient reduction and symptomatic improvement lasting 3–6 months in most patients. As a palliative procedure — not a bridge to TAVR — it can restore enough functional capacity for the patient to attend meaningful events, spend quality time at home, or complete legacy goals. Discuss with interventional cardiology at enrollment as a comfort option before the patient becomes too frail to tolerate even this procedure. 30-day mortality ~5–8%; stroke ~1–2%. The risk-benefit calculus changes when the goal is quality months, not long-term valve durability. Registry data show functional improvement in 70–80% of patients for the first 3 months post-BAV.^[22]

Careful Diuresis Protocol for AS Preload Optimization

Grade A

Furosemide 20–80 mg PO daily; adjust by 20 mg q48–72h based on daily weight, dyspnea, and blood pressure

AS patients are uniquely preload-dependent. The hypertrophied, non-compliant LV requires adequate filling pressure to generate forward output through the fixed obstruction. The therapeutic range for diuresis is narrow: too little diuresis causes pulmonary edema and dyspnea; too much causes hypotension and syncope. Daily weight monitoring with a target weight that balances dyspnea relief against hemodynamic stability is the cornerstone of AS medical management. The clinical target is "damp, not dry" — the AS patient should have mildly elevated JVP and mild peripheral edema to ensure adequate preload. This is the opposite of the CHF management target for most other cardiac diagnoses. ACC/AHA guidelines support diuresis for symptom relief in inoperable severe AS.^[6]^[7]

Rate Control for AF in Severe AS

Grade A

Metoprolol succinate 12.5–25 mg PO daily; target HR 60–80 bpm

AF causes acute hemodynamic decompensation in AS because the non-compliant hypertrophied LV depends critically on atrial contraction ("atrial kick") for adequate ventricular filling. Loss of atrial kick with AF reduces cardiac output by 25–40% in the stiff AS ventricle — far more than in a normal heart. Rate control to 60–80 bpm is the immediate comfort goal. Beta-blocker at low doses preserves filling time without excessive negative inotropy. Avoid digoxin as sole rate agent in AS — less effective and narrow therapeutic index in the elderly. Cardioversion for new-onset AF is appropriate even in comfort-focused care if the hemodynamic impact is severe — restoring sinus rhythm can be the single most impactful comfort intervention in an AS patient who acutely decompensated with AF onset.^[24]

Opioids for Dyspnea and Angina Symptom Management

Grade A

Morphine sulfate 2.5–5 mg SQ/PO q4h PRN; titrate to dyspnea and angina relief

Opioids reduce dyspnea perception by modulating the central respiratory drive, reduce myocardial oxygen demand by decreasing anxiety and work of breathing, and provide direct angina relief. Systematic review evidence supports opioids for refractory dyspnea in heart failure including valvular etiologies. In AS, morphine provides meaningful comfort without significant vasodilation at standard doses — the hemodynamic effect is modest compared to nitrates or ACE inhibitors. Start low, titrate to effect. SQ conversion as oral route fails in advanced disease. Do not withhold opioids from an AS patient with dyspnea or angina — this is the most undertreated symptom in AS hospice care.^[25]

Gentle Positioning and Activity Modification

Grade C

Elevate head of bed 30–45°; avoid sudden position changes; avoid Valsalva maneuvers

Orthopnea and paroxysmal nocturnal dyspnea are prominent symptoms in AS with pulmonary congestion. Elevating the head of bed reduces preload to the congested lungs and improves breathing without pharmacological intervention. Avoid sudden position changes — the fixed obstruction prevents the cardiac output from increasing to compensate for orthostatic blood pressure drops, causing presyncope or syncope. Avoid Valsalva maneuvers (straining at stool, heavy lifting) which transiently reduce preload and can cause syncope. Stool softeners should be standard. Expert consensus and physiological rationale support these measures despite the absence of AS-specific trials.^[6]

Palliative Inotropic Support in Selected Patients

Grade C

Continuous low-dose milrinone or dobutamine infusion via ambulatory pump at home

In highly selected patients with severe AS, reduced EF, and refractory heart failure symptoms who are TAVR-ineligible, continuous home inotropic infusion may improve functional capacity and reduce hospitalization. Dobutamine (2.5–5 mcg/kg/min) or milrinone (0.125–0.25 mcg/kg/min) via ambulatory infusion pump. This is a comfort-focused intervention — it does not extend survival, but it may improve quality of life in the final months. Requires central line placement and infusion pump management. Not standard practice but used in specialized palliative cardiac programs. Milrinone carries vasodilatory risk — use with extreme caution and close BP monitoring in AS.^[27]

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications. Severe AS creates the most restrictive supplement environment in all of cardiac hospice — vasodilation is the defining danger.

🚨 Vasodilation is the defining danger in severe aortic stenosis

The fixed mechanical obstruction of the calcified valve means that any reduction in peripheral vascular resistance causes blood pressure to fall without a compensatory increase in cardiac output — because the cardiac output is locked by the valve. Any supplement with vasodilatory, hypotensive, or preload-reducing effects can cause syncope, hemodynamic collapse, or acute coronary ischemia in an AS patient. Before recommending or allowing any supplement, ask one question: does this lower blood pressure or dilate blood vessels? If the answer is yes, it is contraindicated. This is a uniquely restrictive pharmacological environment.^[6]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"With most of my cardiac patients, I have a long list of supplements that are fine. With AS, the list of what's safe is short, and the list of what can hurt them is long. I tell families: 'Anything that relaxes your blood vessels is off the table. That includes a lot of things that sound harmless — beet juice, L-arginine, high-dose garlic. If it says it supports blood pressure on the bottle, put it back on the shelf.'"

— Waldo, NP

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Coenzyme Q10 (Ubiquinol)	Grade C	100–200 mg daily	Mitochondrial cofactor in cardiac myocytes; theoretical benefit in the energy-deprived hypertrophied LV. Some evidence of improved functional capacity in heart failure. No AS-specific RCT data, but one of the safer supplements given no vasodilatory effect.^[28]	Minor warfarin interaction — may reduce INR slightly in anticoagulated patients; monitor INR if initiating. No significant hemodynamic effects. Generally well tolerated.
Magnesium Glycinate	Grade C	200–400 mg daily	Magnesium depletion is common from chronic diuretic use; supplementation reduces arrhythmia risk, supports neuromuscular function, and may improve sleep quality. Important in AF prevention given the catastrophic hemodynamic impact of AF in AS.^[29]	Safe in mild-moderate renal function (GFR >30). Check serum magnesium before starting — avoid in hypermagnesemia. No vasodilatory effect at oral replacement doses. Reduce dose or avoid in severe CKD.
Melatonin	Grade C	1–3 mg at bedtime	Sleep disruption from orthopnea, dyspnea, anxiety, and nocturnal symptoms is pervasive in severe AS. Melatonin improves sleep onset and quality without hemodynamic effects. One of the safest supplements in this population.^[30]	No vasodilatory effect. Minimal drug interactions. May cause morning drowsiness at higher doses — start at 1 mg. Safe with anticoagulants. Avoid doses >5 mg.
Ginger (Low Dose)	Grade B	250–500 mg daily maximum	Nausea from low cardiac output, hepatic congestion, and medication side effects. Ginger has antiemetic properties with good evidence from chemotherapy nausea trials that generalizes to other nausea etiologies. Minimal hemodynamic effect at low doses.^[31]	Mild antiplatelet effect at doses >1 g/day — limit to 500 mg/day in patients on anticoagulation or antiplatelet therapy. Minimal hemodynamic effect at recommended dose. Avoid high-dose ginger extracts.

🚫 Avoid in Severe Aortic Stenosis

All nitrate-containing herbs and supplements (beetroot juice, L-arginine, L-citrulline): Organic nitrates cause vasodilation equivalent to pharmaceutical nitrate therapy. In fixed-obstruction AS, nitrate-induced vasodilation causes severe hypotension without compensatory cardiac output increase — syncope, hemodynamic collapse, and myocardial ischemia can result. Beetroot juice is commonly promoted as "heart healthy" and is specifically dangerous in AS.^[6]
Hawthorn (Crataegus): Vasodilatory and mild inotropic effects. Often recommended for "heart health" in natural medicine literature. The vasodilatory effect makes it contraindicated in severe AS despite theoretical benefit of the inotropic component. Cannot separate the effects — avoid entirely.^[32]
High-dose garlic supplements (>1,200 mg/day): Significant vasodilatory effect at high doses through hydrogen sulfide and nitric oxide pathways. Additive antiplatelet effect in patients on anticoagulation. Culinary garlic in normal cooking amounts is acceptable — concentrated garlic supplements are not.^[33]
High-dose omega-3 fatty acids (>3 g/day): At high doses, omega-3s have a mild blood pressure–lowering effect through vasodilation. Doses ≤2 g/day are generally safe. Avoid concentrated prescription-strength omega-3 preparations (Vascepa, Lovaza) without cardiology consultation. Additive antiplatelet effect with anticoagulants.^[34]
Hibiscus tea (concentrated or supplemental): Demonstrated antihypertensive effect through ACE-inhibitory and vasodilatory mechanisms. Equivalent to a mild ACE inhibitor. This is precisely the mechanism that is dangerous in AS — afterload reduction without output increase. Avoid in any concentrated form.^[35]
CBD oil / high-dose cannabinoids: Vasodilatory effect through CB1 receptor activation and direct vascular smooth muscle relaxation. Orthostatic hypotension is a common side effect. In the AS patient who is already on the edge of hemodynamic compensation, the additional vasodilation from CBD can cause syncope. Low-dose CBD (<25 mg) for anxiety or sleep may be cautiously acceptable — but full disclosure and monitoring are required.^[36]
Ephedra / Ma Huang and all stimulant-containing supplements: Tachycardia increases myocardial oxygen demand in the hypertrophied LV and shortens diastolic filling time — both catastrophic in AS. Arrhythmia risk is compounded. Contraindicated absolutely.^[37]
St. John's Wort (Hypericum perforatum): Potent CYP3A4 inducer — reduces effectiveness of warfarin, digoxin, beta-blockers, and many cardiac medications through accelerated hepatic metabolism. In the AS patient on a carefully titrated cardiac regimen, St. John's Wort can destabilize every medication simultaneously.^[38]

S09Everyone

Timeline Guide

A guide, not a prediction. Severe aortic stenosis without intervention follows one of the most well-defined natural histories in cardiology — but individual trajectory is shaped by symptom type, LV function, comorbidity burden, and the presence or absence of atrial fibrillation.

The natural history of symptomatic severe aortic stenosis without intervention is one of the best-characterized disease trajectories in medicine, defined by Ross and Braunwald in 1968 and confirmed in modern registries.^[1] The classic symptom triad — angina, syncope, and dyspnea — defines prognosis with remarkable consistency: median survival after angina onset is 3–5 years, after syncope 2–3 years, and after dyspnea/heart failure symptoms 1–2 years without intervention.^[2] Patients with low-flow low-gradient severe AS and reduced ejection fraction have the worst prognosis — often months without intervention. The timeline below reflects the medically managed AS patient who is not a TAVR candidate or has declined intervention. Every phase should trigger specific clinical actions and conversations.

YRS–
MOS

Asymptomatic Severe AS (ACC/AHA Stage C1)

Valve area 0.8–1.0 cm²; mean gradient >40 mmHg; peak velocity >4 m/s — severe AS on echocardiography but the patient remains asymptomatic with preserved exercise tolerance^[3]
Left ventricular hypertrophy is substantial — the ventricle is generating pressures of 180–220 mmHg to push blood through the narrowed valve; compensation is maintained but the muscle is under enormous stress
Annual echocardiographic surveillance is standard; exercise stress testing to unmask occult symptoms in selected patients who deny symptoms but have objective evidence of severe AS^[4]
This is the ideal window for advance care planning and TAVR candidacy evaluation — most patients have never been asked: "If this valve gets worse and you develop symptoms, what would you want us to do?"
Palliative integration: Almost never offered at this stage, but advance care planning conversations belong here; establishing goals before symptoms create urgency is the most underutilized intervention in valvular heart disease
Risk of sudden cardiac death is 1–3% per year even in asymptomatic severe AS — low but not zero; this risk increases substantially once symptoms begin^[5]

MOS–
1 YR

Symptom Onset — The Clock Starts

The valve area has crossed below 0.8 cm² and LV compensation fails — the first symptom in most patients is exertional dyspnea; angina begins with exertion; the family notices the patient slowing down, unable to walk distances they could manage months ago^[1]
TAVR evaluation should happen urgently at this stage — if the patient has not been evaluated, this conversation belongs at the first hospice or palliative care encounter; some patients enrolled for "frailty" or "failure to thrive" have TAVR-amenable AS that was never discussed^[6]
If TAVR is declined or not possible, hospice integration should begin here — median survival from dyspnea onset is 1–2 years without intervention; this is the window most commonly missed because "we're still deciding about the valve"
AF may develop at this stage — the dilated left atrium from chronic pressure overload triggers AF, which causes acute decompensation; loss of atrial kick in the non-compliant LV reduces cardiac output by 25–40%^[7]
Clinical priority: Establish diuresis protocol, initiate low-dose beta-blocker if AF or tachycardia, begin opioid therapy for dyspnea, conduct the natural history conversation with patient and family using specific survival numbers
Functional status: NYHA II–III; ambulatory with limitations; still performing some ADLs independently; Katz ADL score 4–6

WKS–
MOS

Progressive Symptomatic Severe AS Without Intervention

Dyspnea with minimal exertion or at rest; NYHA III–IV; syncope episodes may have begun; angina with decreasing activity threshold; multiple hospitalizations for acute decompensation with pulmonary edema^[2]
Diuresis is managing congestion but becomes increasingly difficult — the therapeutic window narrows as cardiac output falls; the patient who was stable on furosemide 40 mg now needs 80–120 mg and is still dyspneic
AF is common at this stage; rate control becomes challenging; anticoagulation adds bleeding risk but stroke risk from AF is significant
TAVR conversation revisited: Is there still a window? Has functional status declined past TAVR eligibility? BAV as palliative option for temporary symptom relief? Or comfort-focused management only?^[8]
Hospice enrollment is most appropriate at this transition — PPS 40–60%; increasing dependence for ADLs; recurrent hospitalizations; clear trajectory of decline
Comfort kit preparation: Morphine for dyspnea and angina, furosemide for acute fluid management, lorazepam for anxiety, midazolam for catastrophic events; syncope response protocol taught to family; NTG protocol (one dose, seated/supine, SBP >110) reviewed explicitly
ICD discussion if EF has reduced: the patient with severe AS and EF <35% who has an ICD needs the deactivation conversation before it delivers shocks during the dying process

DAYS–
WKS

Active Dying from Severe AS

NYHA IV at rest; acute pulmonary edema requiring daily opioids and diuretics; syncope episodes increasing in frequency; periods of confusion from low cardiac output; minimal oral intake; bed-bound or chair-bound^[9]
Diuresis reaches its physiological limit — cardiac output is too low to perfuse the kidneys adequately; rising creatinine, falling urine output, refractory edema despite high-dose diuretics
Morphine becomes the primary comfort medication — scheduled ATC dosing for dyspnea with PRN for breakthrough; titrate to comfort without ceiling anxiety
Specific AS dying pattern: Unlike CHF where fluid overload dominates, AS patients may die from sudden arrhythmia, acute pulmonary edema, or syncope that does not resolve — prepare the family for each scenario explicitly
Family teaching: "There may come a time when they faint and do not wake up. This can happen suddenly. It is not painful — it is the heart unable to deliver enough blood to the brain. If this happens, stay with them, hold their hand, and call us."
Transition oral medications to SQ route as swallowing becomes unreliable; convert oral morphine to SQ at 50% dose equivalent; convert oral furosemide to SQ/IV

HRS–
DAYS

Final Hours

Cheyne-Stokes respiration or agonal breathing; mandibular breathing; mottling of knees and feet; peripheral cyanosis deepening; unresponsive or minimally responsive^[10]
AS-specific risk: Sudden cardiac death from VT/VF is possible at any point — the hypertrophied, ischemic myocardium is electrically unstable; if ICD is still active, deactivate now to prevent shocks during dying; if no ICD, family should know death may be sudden and without warning signs
Terminal pulmonary edema: pink frothy secretions may appear — glycopyrrolate 0.2 mg SQ q4h for secretions; morphine for dyspnea; position upright if possible; gentle oral suctioning; family education: "This is the heart unable to keep fluid from the lungs — the medications are keeping them comfortable"
Continue SQ morphine on schedule — auditory awareness may persist; assume the patient can hear; speak to them directly; encourage family to say what needs to be said
Emergency medications drawn and labeled at bedside: Morphine 5 mg SQ (dyspnea crisis), Midazolam 5 mg SQ (agitation or refractory dyspnea), Glycopyrrolate 0.2 mg SQ (secretions)
After death: Allow family time. Silence the monitors. If ICD is present and not yet deactivated, apply magnet over device. Document time of death and notify attending physician per protocol.

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for severe aortic stenosis without intervention. The hemodynamic constraints of fixed obstruction make this the most restrictive prescribing environment in all of cardiac hospice.

⚠️ Critical Hemodynamic Warning — Read Before Prescribing

Aortic stenosis without intervention creates the most restrictive hemodynamic environment in all of cardiac hospice. Two principles govern every prescribing decision: (1) Maintain preload — the AS patient needs adequate filling pressure; do not over-diurese; the target is "damp not dry." (2) Avoid vasodilation — any drug that reduces peripheral vascular resistance will cause blood pressure to fall without increasing cardiac output because the obstruction is fixed. The drugs that are standard in most cardiac conditions — ACE inhibitors, ARBs, calcium channel blockers, aggressive nitrates — become dangerous in severe AS.^[11] Review every new prescription against these two principles before ordering. When in doubt, start lower and go slower than in any other cardiac hospice patient.

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Furosemide	Loop diuretic / Pulmonary congestion & edema	20–40 mg PO daily; titrate by 20 mg q48–72h	The most important drug in AS symptom management. Target dyspnea relief while preserving adequate preload. DO NOT chase dry weight — the AS patient who is "perfectly dry" is hypotensive and syncopal. Clinical target: mild JVD and trace peripheral edema acceptable. Over-diuresis sign: SBP <90, presyncope, rising creatinine. IV furosemide 40–80 mg for acute pulmonary edema.^[12] Daily weight monitoring mandatory — 2 lbs/day or 5 lbs/week gain = call nurse same day
Morphine	Opioid / Dyspnea + Angina	2.5–5 mg PO/SQ q4h PRN; escalate to ATC	First-line for both dyspnea and angina in AS. Reduces dyspnea perception, reduces myocardial oxygen demand, reduces anxiety. The most undertreated symptom in AS hospice is dyspnea — do not withhold. SQ conversion 50% of oral dose when swallowing fails. Titrate without ceiling to comfort. Add scheduled bowel regimen on day one.^[13]
Metoprolol succinate	Beta-blocker / Rate control + angina	12.5–25 mg PO daily	Use very low doses in AS. Reduces heart rate (decreases myocardial oxygen demand for angina) and controls AF rate (target HR 60–80 bpm). The non-compliant AS ventricle depends on atrial kick and adequate filling time — tachycardia is poorly tolerated. ⚠ Caution: Do NOT use high-dose beta-blocker in AS with EF <30% — negative inotropy may precipitate cardiogenic shock.^[14] Hold if HR <55 or SBP <95 mmHg
Nitroglycerin (NTG)	Nitrate / Angina (restricted use)	0.3 mg SL x1 dose ONLY	⚠ HIGH-RISK IN AS: NTG causes vasodilation → blood pressure drops → fixed obstruction prevents compensatory output increase → syncope, ischemia, or cardiovascular collapse. Modified AS protocol: ONE dose only; patient must be seated or supine; SBP must be >110 mmHg; call nurse immediately if no relief or lightheaded. NEVER repeat without clinician assessment. NEVER give standing. Many clinicians withhold NTG entirely in severe AS — this is a defensible decision.^[15]
Spironolactone	Aldosterone antagonist / Fluid + fibrosis	12.5–25 mg PO daily	Adjunctive diuretic with anti-fibrotic properties in LV hypertrophy. Potassium-sparing — monitor K+ weekly during initiation, especially if on ACE inhibitor or renal function impaired. Anti-aldosterone effect may reduce myocardial fibrosis progression. Discontinue if K+ >5.5 or creatinine rising significantly.^[16]
Metolazone	Thiazide-like diuretic / Diuretic resistance	2.5 mg PO 30 min before furosemide	Synergistic with loop diuretics for refractory fluid overload. Use short courses (2–3 days) then reassess. Extremely potent — can cause rapid electrolyte shifts and volume depletion. ⚠ Monitor electrolytes and renal function closely. Stop immediately if SBP drops or creatinine rises sharply.
Apixaban	DOAC / AF anticoagulation	5 mg PO BID (2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5)	AF and AS coexist frequently; stroke risk is significant (CHA₂DS₂-VASc typically ≥3). Preferred DOAC — no INR monitoring, fewer drug interactions than warfarin. Consider discontinuing when prognosis is weeks and fall risk is high — the bleeding risk begins to exceed the stroke prevention benefit. Goals-of-care discussion should include anticoagulation decision.^[17]
Lorazepam	Benzodiazepine / Anxiety	0.5–1 mg PO/SL/SQ q4–6h PRN	For anxiety component of dyspnea, syncope fear, and existential distress. Adjunctive — not first-line for dyspnea alone. Sublingual formulation useful when oral route unreliable. Avoid scheduled use unless breakthrough is frequent (>3 PRN doses/day). Monitor for oversedation in elderly with low cardiac output.^[18]
Midazolam	Benzodiazepine / Terminal agitation + catastrophic events	2.5–5 mg SQ PRN; or 10–30 mg/24h CSCI	For terminal agitation, refractory dyspnea, and catastrophic symptom management. Have pre-drawn and labeled at bedside in final weeks. CSCI for sustained refractory symptoms. Document clinical reasoning. Family education before first dose: "This medication will help them rest — it may make them more sleepy, and that is appropriate and intentional."
Glycopyrrolate	Anticholinergic / Terminal secretions	0.2 mg SQ q4h PRN; or 0.6–1.2 mg/24h CSCI	Reduces terminal secretions and secretions from pulmonary edema without CNS effects. Preferred over hyoscine in conscious patients. Family education: "The rattling sound is not distressing to your loved one — the noise sounds much worse than it feels." Repositioning and gentle oral suctioning as adjuncts.^[19]
Mirtazapine	Antidepressant / Depression + insomnia + anorexia	7.5 mg PO QHS	First-line antidepressant in hospice — addresses depression, insomnia, and anorexia simultaneously. Faster onset than SSRIs in this population (benefit within 1–2 weeks). Sedating properties useful for sleep disruption from orthopnea and nocturnal dyspnea. Safe hemodynamic profile — no significant vasodilation or cardiac effects. Screen every AS patient for depression at enrollment.^[20]
Magnesium glycinate	Electrolyte / Arrhythmia prevention	200–400 mg PO daily	Diuretic use depletes magnesium; hypomagnesemia increases arrhythmia risk in the already electrically unstable AS myocardium. Check serum magnesium; target >2.0 mEq/L. Safe in mild-moderate renal function. Reduce dose if eGFR <30. Glycinate formulation preferred — better absorbed, less GI upset than oxide.^[21]

🚫 Medications to STOP or AVOID in Severe AS

ACE inhibitors / ARBs (lisinopril, losartan, valsartan) — vasodilation drops BP without increasing output through fixed obstruction; stop at enrollment if presyncope, hypotension, or SBP <110^[11]
Dihydropyridine CCBs (amlodipine, nifedipine) — peripheral vasodilators; contraindicated in severe symptomatic AS
Alpha-blockers (doxazosin, tamsulosin) — vasodilation; common BPH medications that cause syncope in AS patients; tamsulosin has less alpha-1 vascular selectivity than often assumed
Aggressive nitrate dosing — NTG at standard doses causes hemodynamic collapse; isosorbide dinitrate/mononitrate should be discontinued
PDE-5 inhibitors (sildenafil, tadalafil) — profound vasodilation; absolutely contraindicated
Non-DHP CCBs at high dose (verapamil, diltiazem) — negative inotropy + vasodilation; use only if metoprolol contraindicated and at lowest effective dose for AF rate control

🌿 Symptom Management Decision Tree — Aortic Stenosis

Evidence-based · AS-specific · Hospice-adapted

Select a symptom below to begin

What is the primary symptom to address?

🚨 Comfort Kit Must-Haves for Severe Aortic Stenosis

Acute pulmonary edema: Morphine 5 mg SQ (pre-drawn) + Furosemide 40 mg IV/SQ (pre-drawn) — DO NOT give NTG for pulmonary edema in AS
Syncope that doesn't resolve / cardiac arrest: Midazolam 5 mg SQ (pre-drawn) for prolonged unconsciousness with distress; family knows to lower patient to floor safely, not give food/water, call nurse
Severe refractory dyspnea: Morphine 5 mg SQ + Midazolam 2.5 mg SQ — pre-drawn and labeled, accessible to trained caregiver
Terminal agitation: Midazolam 5 mg SQ PRN (pre-drawn) + Haloperidol 1 mg SQ if delirium component
Terminal secretions: Glycopyrrolate 0.2 mg SQ (pre-drawn) — family instructed on administration timing
Breakthrough angina: Morphine 2.5 mg SQ — safer than NTG in most AS patients; NTG only with specific clinician protocol in place

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team managing severe aortic stenosis. The things not in the textbook — learned at the bedside over years of managing a disease where the valve cannot be fixed and every prescribing decision walks a hemodynamic tightrope.

The prognosis conversation has almost certainly not been had

At the first visit, ask directly: "Do you know what the prognosis is with the valve the way it is, without the procedure?" The answer is almost always no, or vague. Median survival after dyspnea onset is 1–2 years without intervention. After syncope, 2–3 years. With heart failure and low-flow low-gradient AS, often months.^[1] This number must be communicated clearly and compassionately. The family and patient who do not know this number cannot make fully informed decisions about advance care planning, legacy work, family time, and goals. Most cardiologists have delivered this obliquely or not at all. The hospice clinician's first and most important contribution is to say the number — and then build the care plan around it.

Vasodilator avoidance is the single most important medication principle

ACE inhibitors, ARBs, nifedipine, amlodipine, alpha-blockers, and aggressive nitrate use all reduce afterload. In a normal heart, this increases cardiac output. In fixed-obstruction AS, the cardiac output cannot increase because the valve is the bottleneck — blood pressure falls without output rising. Syncope, coronary ischemia, and acute decompensation follow.^[11] At enrollment, review every medication for vasodilatory properties. Stop what should be stopped. Dose-adjust what must continue. The patient who arrives on lisinopril "for blood pressure" and is having presyncope may simply need that medication stopped — and that single change may be the most impactful comfort intervention you make at the first visit.

The diuresis target in AS is different from every other cardiac diagnosis

Most cardiac patients are diuresed to dry weight with minimal JVD. AS patients are diuresed to "damp" weight with mild JVD and trace peripheral edema acceptable — intentionally.^[12] The AS left ventricle is stiff and non-compliant from hypertrophy and requires higher filling pressures to generate adequate stroke volume. An AS patient who is "perfectly dry" by CHF standards may be syncopally hypotensive. Teach the family: "Some ankle swelling and slight vein fullness in the neck are expected and intentional — they mean the heart has enough blood to pump." The sign of too much diuresis: SBP <90, presyncope, rising creatinine. Back off before you push further.

Syncope in AS is a high-risk event — assess every episode in real time

After a syncopal episode in severe AS, the risk of sudden cardiac death in the near term is meaningfully elevated.^[5] Assess every syncope event at the time it occurs — call-in assessment is acceptable for brief, self-resolving episodes, but increasing frequency or prolonged episodes warrant urgent visit. Document the frequency and circumstances of each episode. Three or more syncope events in a month typically indicates weeks-to-months prognosis. Teach the family the syncope response protocol before the first event: lower to floor safely, do not give food or water until fully conscious, note duration, call nurse. The family who was briefed is confident. The family who was not is traumatized.

AF in AS is a medical emergency, not a chronic nuisance

The non-compliant, hypertrophied AS ventricle depends critically on the atrial contraction ("atrial kick") for 25–40% of its cardiac output. Loss of atrial kick with AF onset causes acute, often dramatic decompensation — sudden worsening of dyspnea, new or worsened pulmonary edema, syncope, or hypotension.^[7] New-onset AF in an AS patient requires urgent rate control to HR 60–80 bpm. Metoprolol at low doses is first-line. Consider cardioversion if onset was clearly <48 hours ago and the patient decompensated acutely. Start anticoagulation unless actively dying. Document the AF onset — it is a prognostically significant event that often marks the transition to the final months.

The NTG instruction in AS is different from every other cardiac patient

Standard angina protocol is "take NTG, repeat every 5 minutes times 3, then call 911." In severe AS, this protocol can kill. Nitroglycerin causes vasodilation — blood pressure drops — the fixed obstruction prevents compensatory cardiac output increase — the patient becomes hypotensive, syncopal, or suffers acute coronary ischemia from the very medication meant to relieve it.^[15] The AS-specific NTG protocol: ONE dose, patient must be seated or supine, SBP must be >110 mmHg, call the nurse immediately if no relief or if lightheaded. Do NOT repeat. Do NOT give standing up. Many hospice clinicians withhold NTG entirely and use morphine as the primary angina reliever in AS — this is a defensible and often safer approach.

Ask about TAVR status at enrollment — even if the chart says "not a candidate"

Some patients enrolled on hospice for "frailty" or "failure to thrive" have severe AS that was never fully evaluated for TAVR, or that was declined at one center but might be reconsidered at another.^[6] Some patients were told "you're not a candidate" without full heart-team evaluation. Ask: "Were you ever evaluated at a center that does TAVR? Did a heart team — a surgeon and a cardiologist together — review your case?" If the answer is no, and the patient's goals include extending life, the conversation about a second opinion belongs at hospice enrollment. This is not contradicting hospice philosophy — this is ensuring fully informed decision-making. Some patients leave hospice to pursue TAVR. That is a good outcome.

Racial, ethnic, and sex disparities in TAVR access are documented and significant

Black and Hispanic patients are significantly less likely to be referred for TAVR evaluation than White patients with equivalent AS severity and surgical risk profiles.^[22] Women are referred for TAVR later, with more advanced symptoms and worse functional status, and experience higher peri-procedural complications when they do undergo TAVR — partly because devices were designed for male anatomy.^[23] The hospice clinician who asks "have you been evaluated for TAVR?" is performing an equity intervention — not just a clinical one. If the patient says no, and they are from a group that is historically under-referred, advocate for evaluation. The goal is not to push TAVR on everyone — it is to ensure every patient had an equal opportunity to be considered.

ICD deactivation conversation belongs at enrollment, not at the code

Patients with severe AS and reduced EF (<35%) may have an ICD in place. An ICD that fires during the dying process delivers painful electrical shocks to a patient who cannot benefit from resuscitation — and traumatizes the family who watches it happen.^[24] At enrollment, assess: Does the patient have an ICD? Is it active? What are the patient's wishes about shocks in the final phase of life? The conversation should include: "This device is designed to restart your heart if it stops. As we get closer to the end of life, your heart may develop rhythms that trigger the device. We can turn off the shock function while keeping the pacemaker function if you want — so you don't receive painful shocks when the time comes." Most patients choose deactivation once they understand the scenario. Have this conversation early. Document it. Arrange electrophysiology for deactivation.

The caregiver of the AS patient carries specific burdens — name them proactively

The caregiver of a patient with severe AS lives with the constant fear of sudden death — the knowledge that their person could faint and not wake up, could develop acute pulmonary edema, or could die suddenly from arrhythmia.^[25] This creates hypervigilance, sleep disruption (the caregiver who checks breathing every hour), and anticipatory grief that is qualitatively different from the slow-trajectory grief of cancer caregiving. Additionally, the caregiver of a patient who declined TAVR or was declined for TAVR may carry resentment, guilt, or unresolved anger about the decision. Address both directly: "I want to check in on you, not just your [person]. Living with the worry that something sudden could happen is exhausting. Are you sleeping? Are you eating? Can we talk about what you're afraid of?"

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The AS patient who comes onto service on lisinopril, amlodipine, and a high-dose diuretic with presyncope three times a week — that patient doesn't need more medications. They need fewer. Stop the vasodilators. Back off the diuretic. Add morphine for the dyspnea. I've had patients go from barely getting out of bed to walking to the kitchen just by stopping the drugs that were killing their blood pressure through a valve that couldn't compensate. Sometimes the best intervention isn't adding something — it's taking something away."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

The TAVR grief, the syncope terror, the invisibility of the symptom, and the existential weight of living with an irreversible mechanical obstruction. The symptom burden you cannot see on a vitals sheet.

Psychosocial distress in severe aortic stenosis managed without intervention carries disease-specific dimensions that differ fundamentally from cancer hospice and from other cardiac diagnoses. The patient with medically managed severe AS is living with the knowledge that a specific, identifiable mechanical problem — a calcified valve — is killing them, and that a procedure exists to fix it but is either not available to them or has been declined.^[26] This creates a psychological landscape of grief, fear, and existential reckoning that requires targeted intervention.

The TAVR Grief

TAVR Refusal — "You Are Not a Candidate"

For patients who were referred, evaluated, and declined for TAVR, the refusal is experienced as a verdict of unworthiness. They were told the procedure that could save them is not available to them. The reasons — too frail, too sick, anatomy too hostile, comorbidities too severe — feel like personal failures rather than medical realities.^[27]

Name this grief explicitly: "Being told you cannot have the procedure is not a reflection of how hard you have fought or how much your life matters. It is a statement about what the valve and your body can safely withstand right now."
Validate the anger: many patients feel betrayed by a medical system that detected the problem, described a solution, and then told them they couldn't have it
Screen for depression: TAVR refusal is an independent risk factor for depressive symptoms in AS patients
Reassess periodically — some patients improve with medical optimization enough to be reconsidered for TAVR

Patient-Directed Refusal — Family Grief

When the patient has chosen to decline TAVR against family wishes, the family carries specific grief and anger about the decision. Some family members cannot accept that the patient declined an intervention that might have helped.^[28]

Protect the patient's autonomy absolutely: the patient who makes an informed decision to decline intervention has exercised the most fundamental right in medicine
Honor the family's grief: "I understand how painful it is to watch someone you love make a choice you disagree with. Your feelings are completely valid."
Mediate when needed: help the family understand that refusing a procedure is not refusing life — it is choosing a different relationship with the time that remains
Involve social work and chaplain early — this is not a medical problem; it is a relational and existential one

Disease-Specific Psychological Dimensions

Syncope Terror

The AS patient who has syncopized carries profound fear of the next episode — fear of falling, of being found on the floor, of dying suddenly without warning, of losing consciousness in public^[29]
This fear creates activity restriction, social isolation, and hypervigilance that erode quality of life independently of the physical symptoms
Intervention: Teach the syncope response protocol to the family — when the patient knows their family is prepared, the fear diminishes; Lorazepam 0.5 mg PRN for acute anxiety; normalize the fear: "Being afraid of fainting is completely reasonable. Let's make sure you and your family know exactly what to do so you're not facing it without a plan."
Activity counseling: avoid straining, avoid hot environments, avoid standing quickly; seated activities maintain social engagement without exertional syncope risk

Invisibility of the Symptom

AS symptoms — dyspnea, fatigue, reduced exercise tolerance — are invisible to observers and are often minimized by patients who have adapted over years to declining capacity
Families may not understand how severe the physiological compromise is because the patient "looks fine sitting in the chair"
The prognosis conversation anchors understanding: using specific survival numbers makes the severity real without requiring visible symptoms to make it credible
Validate the patient: "The fact that you look okay sitting here doesn't mean you are okay. Your heart is working at maximum effort just to keep you in that chair. That is exhausting, and it is real."

Spiritual Assessment

Use the FICA framework: Faith/beliefs, Importance, Community, Address. The AS patient facing a mechanical, irreversible problem often wrestles with questions of fairness and divine will: "Why would God let this happen when there's a fix but I can't have it?" This is a specific spiritual crisis that differs from the cancer patient's crisis of meaning. Chaplain referral at enrollment — not at crisis.^[30]

Clinical Pearl

"The patient who says 'I've made peace with it' at the first visit often hasn't. Give them three visits before you believe it. Peace with a terminal diagnosis is a process, not an event — and the patient who performs peace for you is not necessarily experiencing it. Ask again. Ask differently. Ask when the family isn't in the room."

Goals-of-Care Communication

Opening the Conversation in AS

"What is your understanding of where things stand with your heart valve?" — assesses illness understanding; most patients have never been told specific prognosis numbers
"Has anyone talked to you about what to expect over the next year without the valve procedure?" — opens the natural history conversation
"What are you most afraid of?" — in AS, the answer is often "fainting and dying" or "not being able to breathe" — name it, normalize it, address it
"If you had a choice between more time and more comfort, which matters more to you right now?" — elicits priorities for the diuresis-vs-blood-pressure balance

Communication Pitfalls in AS

Don't say "there's nothing we can do about the valve": This is technically true but psychologically devastating — reframe: "The valve cannot be fixed with surgery right now, but there is a great deal we can do to help you feel better and live well."
Don't minimize the TAVR grief: "At least you don't have cancer" is harmful — every terminal diagnosis has its own weight
Don't avoid the survival numbers: Vague reassurance ("everyone is different") without specific data denies the patient the information they need to make decisions
Don't assume the patient was told everything by their cardiologist: Studies consistently show that patients with AS have poor understanding of their prognosis even after cardiology consultations^[31]

Suicidal Ideation & Hastened Death Requests

Passive wish for death ("I'm ready to go") is common in AS patients facing a known mechanical problem without a fix — and is often existentially appropriate. Distinguish carefully: passive wish for death (common, often appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and desire for hastened death rooted in uncontrolled symptoms (requires aggressive symptom management before assuming it is a psychiatric problem).^[32] The AS patient who says "I wish it would just end" may be expressing poorly controlled dyspnea or angina, not suicidal ideation. Treat the symptoms first. If the wish persists after symptom optimization, engage psychiatry and chaplain.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The hardest TAVR grief I've seen isn't the patient who was told no — it's the spouse who begged them to have the procedure and they refused. That spouse is sitting in the room watching their person die from something they believe could have been fixed. You cannot fix that. But you can name it: 'I see how painful this is for you. Your feelings matter too.' That one sentence changes the room."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for families. Share, print, or read aloud at the bedside.

Your loved one has a condition called severe aortic stenosis — the main valve that controls blood flow out of the heart has become stiff and narrowed over time. The heart has been working harder and harder to push blood through this narrowed opening, and now it is reaching the limits of what it can do. There is a procedure called TAVR that can help some patients, but your person's medical team has determined that it is not the right option right now — or your loved one has chosen not to have it. Either way, we are here to help them live as comfortably as possible for as long as possible. This guide will help you understand what to expect and how you can be part of the care team.

Próximamente en español. — Coming soon in Spanish.

What You May See

Shortness of breath — especially with exertion and when lying flat. This is the narrowed valve limiting blood flow. Sitting up and using pillows to elevate the head of the bed helps significantly. Medications help too. Do not wait to report breathing that is not improving with the current plan — call the nurse.
Fainting or near-fainting (syncope). Sudden loss of consciousness without warning is possible with this condition. This happens because the heart cannot deliver enough blood to the brain during exertion or when blood pressure drops. Your nurse will teach you a specific response protocol — learn it before it happens, not after.
Chest pressure or tightness (angina). The heart muscle is not getting enough blood through the narrowed valve. There is a specific protocol for using nitroglycerin in this condition that is different from what you may have heard for regular heart patients. Follow exactly what your nurse instructs — the standard "take three NTG" rule does not apply here.
Significant fatigue. The heart is working at maximum effort at all times just to push blood through the narrowed opening. Even minimal activity can be exhausting. Rest is not laziness — it is the body conserving what the heart can provide.
Swelling in the ankles and legs. The heart is not keeping up with fluid. Daily weight monitoring tells your nurse when to adjust the water pill. Some mild swelling is expected and intentional in this condition — it helps the heart pump better.
Lightheadedness when standing. The narrow valve cannot respond quickly to position changes. Help your person stand up slowly — sit at the edge of the bed for two minutes before standing. Hold onto something stable. Call the nurse if this happens frequently.

How You Can Help

Weigh every morning at the same time, before eating, in the same clothes. Write it down. A gain of 2 pounds in a day or 5 pounds in a week means call the nurse the same day. This is the single most important daily action you can take — it tells us whether the heart is keeping up with fluid before symptoms get worse.
Know the syncope response protocol your nurse reviewed. If they faint: lower them to the floor safely (do not try to catch them — protect their head). Do not give food or water until they are fully awake and alert. Call the nurse immediately. Note how long they were unconscious. Do not call 911 unless specifically instructed by your nurse or if they do not regain consciousness.
Follow the exact nitroglycerin instruction your nurse gave. The medication that helps chest pain in most heart patients can be dangerous in this condition if used incorrectly. ONE dose only. They must be sitting or lying down. Call the nurse immediately if not better or if they feel lightheaded. Do NOT give a second dose on your own.
Keep the head of the bed elevated 30–45 degrees. Extra pillows or a hospital bed wedge helps breathing significantly, especially at night. If they wake up gasping, sit them upright immediately and call the nurse.
Encourage rest without guilt. Activities should be seated when possible. Short walks with support are fine if tolerated, but stop immediately if they feel dizzy, short of breath, or have chest pressure. There is no benefit to "pushing through it" with this condition.
Take care of yourself. Caring for someone with this condition means living with uncertainty — the worry that something sudden could happen is real and exhausting. Call us when you need support, not just when the patient does. You are part of our team, and we are here for you too.

📞 Call the nurse immediately if you see:

Fainting that lasts more than 1 minute or fainting that is happening more often than before · Sudden severe shortness of breath that does not improve with sitting upright and morphine · Chest pain that does not go away after one nitroglycerin dose (given per the nurse's specific instructions) · Pink or frothy sputum when coughing — this means fluid in the lungs and needs urgent attention · A weight gain of 3+ pounds overnight · New confusion or inability to stay awake — this may mean the heart is not delivering enough blood to the brain · An ICD shock — if they have a defibrillator device and it fires, call us immediately.

🙏 Your presence matters more than you know. Research consistently shows that patients who have engaged, informed family caregivers experience better symptom control and less distress — not just emotionally, but physically. Every time you take a weight, follow a medication instruction, or simply sit quietly beside them, you are providing care that no professional can replace. You are not watching from the sidelines. You are part of the team doing the most important work.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after managing enough severe AS patients without intervention. Not guidelines — real.

01
Say the natural history number at the first visit. Median survival after dyspnea onset is 1–2 years without intervention. Most patients have never heard this number from their cardiologist. I don't care how uncomfortable it makes you — the family operating on "years and years" cannot make fully informed decisions about how to spend their time. Sit down. Make eye contact. Say: "Based on what we know about this valve and your symptoms, without the procedure, most patients have about one to two years. I want to make sure we use that time in the way that matters most to you." The conversation that follows is the most important one you will have with this family. Do not skip it. Do not soften it into meaninglessness. Be kind and be clear. They deserve both.
02
Vasodilator avoidance is the defining pharmacological principle in AS — and the most common medication error I see at enrollment. I cannot count the number of AS patients I've admitted who were on lisinopril, amlodipine, or both — having presyncope multiple times a week — and nobody connected the dots. Review every single medication at the first visit for vasodilatory properties. ACE inhibitors, ARBs, nifedipine, alpha-blockers (yes, tamsulosin counts), aggressive nitrate dosing — all of them drop blood pressure without increasing output through the fixed obstruction. Stopping a vasodilator in an AS patient can be the most impactful comfort intervention you make. I've had patients who went from three syncopal episodes a week to zero just by stopping the lisinopril. It's not complicated. It just requires someone to look at the med list through the lens of AS hemodynamics.
03
The diuresis target is "damp not dry" — and this is the opposite of what most cardiac nurses were taught. Every other cardiac patient gets diuresed to dry weight. The AS patient gets diuresed to a level where dyspnea is relieved but mild JVD and trace peripheral edema remain acceptable. The hypertrophied non-compliant LV needs higher filling pressures. If your AS patient is perfectly dry with no peripheral edema and is having presyncope — the diuretic dose is too high. Back off. I teach families: "A little bit of ankle swelling means the heart has enough blood to pump. If the ankles are thin and they're dizzy, we need to give the heart more to work with." This is counterintuitive for families who've been told swelling is bad. Explain it. They'll get it.
04
Teach the syncope response protocol before the first syncope event, not after. The family who watched their person collapse without knowing what to do is traumatized. The family who was briefed, practiced, and confident is not. It takes five minutes: lower to the floor safely, protect the head, do not give food or water until fully alert, note the time, call the nurse. I teach this at the first visit — every time. I say: "There may be a time when they lose consciousness briefly. It may be frightening, but it is usually not painful for them. Here's exactly what to do." We practice it. We write it on the fridge. And when it happens, the daughter calls me calm and informed instead of calling 911 in a panic. Five minutes of teaching saves hours of crisis.
05
The NTG instruction in AS is different from every other cardiac patient — and the standard protocol can kill. "Take one, wait five minutes, take another, wait five minutes, take a third, then call 911." That protocol was written for patients with normal valves. In severe AS, the second or third dose of NTG can drop blood pressure through the floor because the fixed obstruction prevents compensatory cardiac output increase. I teach one dose, sitting or lying down, SBP must be above 110, and then call me. No second dose without clinician instruction. Honestly, for many of my AS patients, I skip NTG entirely and use morphine as the primary angina reliever. It's safer, it works, and there's no risk of hemodynamic collapse. Write the NTG protocol on a card that stays with the NTG bottle. Don't rely on the family remembering a verbal instruction during an angina episode.
06
Ask about BAV (balloon aortic valvuloplasty) as a palliative option before the patient becomes too frail to tolerate even that. BAV isn't a cure — the valve re-narrows in 3–6 months. But it can reduce the gradient enough to relieve symptoms temporarily, allow better diuresis, and give the patient a window of improved function. I've had patients get BAV and then attend a granddaughter's wedding, or have three comfortable months at home instead of three miserable ones. The conversation with interventional cardiology should happen at enrollment while there's still enough functional reserve to tolerate the procedure. Once the patient is bed-bound and in NYHA IV, the window has closed. Don't miss it by waiting too long to ask.
07
The TAVR grief is real, specific, and requires its own clinical attention. The patient who was told "you're not a candidate for the valve procedure" heard: "You are not worth saving." That's not what the heart team said — but it's what the patient heard. Name it directly: "Being told you can't have the procedure doesn't mean your life doesn't matter. It means the procedure itself carries risks that would be dangerous for you right now." Some patients need to hear this more than once. Some families need to hear it even more. The spouse who is angry that their partner was "rejected" for TAVR needs space to express that anger without being corrected. Let them be angry. Then redirect: "What can we do to make the time you have together as good as possible?"
08
The disparities in TAVR access are real — ask every patient about their evaluation history. Black and Hispanic patients are referred for TAVR at significantly lower rates than White patients with the same disease severity. Women are referred later, sicker, and with worse outcomes. Rural patients may never have been evaluated at a TAVR-capable center. When I admit an AS patient, I ask: "Were you ever seen at a hospital that does TAVR? Did a heart team — a surgeon and cardiologist together — review your case?" If the answer is no, and the patient wants to know more, I facilitate that referral. This is not anti-hospice. This is pro-equity. Every patient deserves an equal chance to be evaluated, regardless of their zip code, their race, or their insurance. The ones who end up back on service after evaluation are at least making informed decisions.
09
The caregiver of the AS patient lives in constant fear of sudden death — and nobody asks about it. Cancer caregivers have a trajectory they can see. AS caregivers have a trajectory and a bomb — the possibility that their person will faint and not wake up, or develop acute pulmonary edema in the middle of the night, or die suddenly from an arrhythmia. That fear doesn't go away. It disrupts sleep, it creates hypervigilance, it erodes the caregiver's health. I ask every caregiver at every visit: "Are you sleeping? Are you eating? What are you most worried about right now?" And I listen to the answer. Sometimes the caregiver needs me more than the patient does. If the caregiver collapses, the patient loses the only person standing between them and a facility. Protect both.
10
When the time comes, some AS patients die suddenly. Prepare the family for that possibility — it is not a failure of your care. The hypertrophied, ischemic, electrically unstable myocardium in severe AS can generate a fatal arrhythmia at any time. You can have the diuresis perfect, the morphine titrated, the family briefed, and the patient comfortable — and they can die without warning in their sleep or during a meal. This is not your failure. This is the disease. Prepare the family: "There may come a time when they pass suddenly and peacefully, without a long decline. If that happens, it means the heart simply stopped — and while it is a shock, it is not a painful way to go." The family who was warned handles it differently from the family who wasn't. And you, the nurse, need to hear this too: a sudden death in a well-managed AS patient is not a clinical miss. It is the natural history of a mechanical problem that was always going to have this ending. Let yourself be at peace with that.

— Waldo, NP

REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38(1 Suppl):61–67.

PMID 4894151 DOIReview

Otto CM, Prendergast B. Aortic-valve stenosis — from patients at risk to severe valve obstruction. N Engl J Med. 2014;371(8):744–756.

PMID 25140960 DOIReview

Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation. 2021;143(5):e72–e227.

PMID 33332150 DOIGuideline

Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30(4):372–392.

PMID 28385280 DOIGuideline

Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005;111(24):3290–3295.

PMID 15956131 DOIObservational

Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–1607.

PMID 20961243 DOIRCT

Stortecky S, Buellesfeld L, Wenaweser P, et al. Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2013;6(1):77–84.

PMID 23386660 DOIObservational

Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2485–2491.

PMID 25788231 DOIRCT

Bach DS, Siao D, Girard SE, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. Circ Cardiovasc Qual Outcomes. 2009;2(6):533–539.

PMID 20031889 DOIObservational

Hui D, dos Santos R, Chisholm G, et al. Clinical signs of impending death in cancer patients. Oncologist. 2014;19(6):681–687.

PMID 24760709 DOIObservational

Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348(18):1756–1763.

PMID 12724482 DOIObservational

Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aortic stenosis in adults. Am Heart J. 1980;99(4):419–424.

PMID 7361129 DOIObservational

Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.

PMID 12958109 DOIRCT

Rossi A, Temporelli PL, Cicoira M, et al. Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis. Int J Cardiol. 2015;190:15–17.

PMID 25912107 DOIObservational

Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373(9667):956–966.

PMID 19232707 DOIReview

Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor ramipril in aortic stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015;16(8):834–841.

PMID 25796267 DOIRCT

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151.

PMID 30686041 DOIGuideline

Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10):CD007354.

PMID 27764523 DOISystematic Review

Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008;(1):CD005177.

PMID 18254073 DOISystematic Review

Rayner L, Price A, Evans A, et al. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med. 2011;25(1):36–51.

PMID 20935027 DOIMeta-analysis

Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2013;127(1):33–38.

PMID 23172839 DOIObservational

Alkhouli M, Alqahtani F, Holmes DR, et al. Racial disparities in the utilization and outcomes of transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(10):936–948.

PMID 31122351 DOIObservational

Chandrasekhar J, Dangas G, Yu J, et al. Sex-based differences in outcomes with transcatheter aortic valve therapy: TVT Registry from 2011 to 2014. J Am Coll Cardiol. 2016;68(25):2733–2744.

PMID 28007134 DOIObservational

Goldstein NE, Lampert R, Bradley E, et al. Management of implantable cardioverter-defibrillators in end-of-life care. Ann Intern Med. 2004;141(11):835–838.

PMID 15583224 DOIReview

Strömberg A, Jaarsma T. Thoughts about death and perceived health status in elderly patients with heart failure. Eur J Heart Fail. 2008;10(6):608–613.

PMID 18486549 DOIObservational

Lauck SB, Baumbusch J, Achtem L, et al. Factors influencing the decision of older adults to be assessed for transcatheter aortic valve implantation: an exploratory study. Eur J Cardiovasc Nurs. 2016;15(2):e8–e17.

PMID 25336395 DOIObservational

Olsson K, Näslund U, Nilsson J, Hörnsten Å. Experiences of and coping with severe aortic stenosis among patients not referred for surgery. J Clin Nurs. 2018;27(5-6):e922–e930.

PMID 29076252 DOIObservational

Lauck SB, Lewis KB, Borber SE, et al. "I am not a candidate": a qualitative study of patients' experiences with referral and non-referral to transcatheter aortic valve replacement. Heart Lung. 2019;48(5):442–449.

PMID 31221496 DOIObservational

Tan C, Ling H, Widger J. Review of syncope in aortic stenosis: assessment and management. Cardiol Rev. 2019;27(4):192–198.

PMID 30570523 DOIReview

Borneman T, Ferrell B, Puchalski CM. Evaluation of the FICA tool for spiritual assessment. J Pain Symptom Manage. 2010;40(2):163–173.

PMID 20619602 DOIObservational

Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125(15):1928–1952.

PMID 22392529 DOIGuideline

Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 2000;284(22):2907–2911.

PMID 11147988 DOIObservational

Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients (PARTNER 2). N Engl J Med. 2011;364(23):2187–2198.

PMID 21639811 DOIRCT

Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients (PARTNER 3). N Engl J Med. 2019;380(18):1695–1705.

PMID 30883058 DOIRCT

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients (EVOLUT Low Risk). N Engl J Med. 2019;380(18):1706–1715.

PMID 30883053 DOIRCT

Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26(6):1522–1528.

PMID 7594080 DOIObservational

Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55(25):2789–2800.

PMID 20579534 DOIReview

Vavalle JP, Bashore TM. Radiation heart disease: review and current perspective. Curr Probl Cardiol. 2019;44(3):87–103.

PMID 29801678 DOIReview

Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol. 2017;70(6):689–700.

PMID 28693934 DOIObservational

Green P, Arnold SV, Cohen DJ, et al. Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). Am J Cardiol. 2015;116(2):264–269.

PMID 25963221 DOIObservational

Clavel MA, Pibarot P, Dumesnil JG. Low-gradient aortic stenosis. Eur Heart J. 2016;37(34):2645–2657.

PMID 27190095 DOIReview

Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42(3):388–399.

PMID 21458217 DOIRCT

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200.

PMID 27206819 DOIGuideline

Galper BZ, Colquhoun D, Gollob MH, et al. ICD deactivation at end of life: a systematic review of clinical practices and physician and patient attitudes. Circ Arrhythm Electrophysiol. 2016;9(8):e004081.

PMID 27516463 DOISystematic Review

Arnold SV, Spertus JA, Lei Y, et al. Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail. 2013;6(1):61–67.

PMID 23230310 DOIObservational

Lindman BR, Clavel MA, Mathew V, et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006.

PMID 27188578 DOIReview

Galante GJ, Bekeredjian R, Engel S, et al. Palliative care in patients with severe aortic stenosis: a scoping review. J Palliat Med. 2021;24(3):422–432.

PMID 33136488 DOISystematic Review

Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–1011.

PMID 16980116 DOIObservational

Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis (SALTIRE). N Engl J Med. 2005;352(23):2389–2397.

PMID 15944423 DOIRCT

Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–742.

PMID 20818875 DOIRCT

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.